Document is current
Any future updates will be listed below
-
Authors
Alcalde-Herraiz, Marta
Català, Martí
Prats-Uribe, Albert
Paredes, Roger
Xie, JunQing https://orcid.org/0000-0002-0040-0042
Prieto-Alhambra, Daniel https://orcid.org/0000-0002-3950-6346
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research
- License Information
-
More Information
Article History
Received: 10 November 2023
Accepted: 23 September 2024
First Online: 9 October 2024
Competing interests
: D.P.A.’s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA’s department. R.P. has participated in advisory boards for Pfizer, Gilead, MSD, GSK, Atea, Lilly, Roche, Astra-Zeneca, ViiV Healthcare and Theratechnologies, has participated in lectures and seminars funded by Gilead, Pfizer, GSK and AstraZeneca, and has received research funds awarded to his institution from Gilead, Pfizer, and MSD. All other authors declare no conflicts of interest.
